Author
Listed:
- Jun Li
(Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center)
- Melissa J. Hubisz
(Weill Cornell Medicine
Meyer Cancer Center, Weill Cornell Medicine
Institute for Computational Biomedicine, Weill Cornell Medicine
Cornell University)
- Ethan M. Earlie
(Weill Cornell Medicine
Meyer Cancer Center, Weill Cornell Medicine
Institute for Computational Biomedicine, Weill Cornell Medicine)
- Mercedes A. Duran
(Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center)
- Christy Hong
(Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center)
- Austin A. Varela
(Weill Cornell Medicine
Meyer Cancer Center, Weill Cornell Medicine
Institute for Computational Biomedicine, Weill Cornell Medicine)
- Emanuele Lettera
(Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center)
- Matthew Deyell
(Weill Cornell Medicine
Meyer Cancer Center, Weill Cornell Medicine
Institute for Computational Biomedicine, Weill Cornell Medicine)
- Bernardo Tavora
(Volastra Therapeutics Inc.)
- Jonathan J. Havel
(Volastra Therapeutics Inc.)
- Su M. Phyu
(University of Oxford)
- Amit Dipak Amin
(Columbia Center for Translational Immunology
Columbia University Medical Center)
- Karolina Budre
(Weill Cornell Medicine
Meyer Cancer Center, Weill Cornell Medicine
Institute for Computational Biomedicine, Weill Cornell Medicine)
- Erina Kamiya
(Weill Cornell Medicine
Meyer Cancer Center, Weill Cornell Medicine
Institute for Computational Biomedicine, Weill Cornell Medicine)
- Julie-Ann Cavallo
(Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center)
- Christopher Garris
(Harvard Medical School
Center for Systems Biology, Massachusetts General Hospital)
- Simon Powell
(Memorial Sloan Kettering Cancer Center)
- Jorge S. Reis-Filho
(Memorial Sloan Kettering Cancer Center)
- Hannah Wen
(Memorial Sloan Kettering Cancer Center)
- Sarah Bettigole
(Volastra Therapeutics Inc.)
- Atif J. Khan
(Memorial Sloan Kettering Cancer Center)
- Benjamin Izar
(Columbia Center for Translational Immunology
Columbia University Medical Center)
- Eileen E. Parkes
(University of Oxford)
- Ashley M. Laughney
(Weill Cornell Medicine
Meyer Cancer Center, Weill Cornell Medicine
Institute for Computational Biomedicine, Weill Cornell Medicine)
- Samuel F. Bakhoum
(Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center)
Abstract
Chromosomal instability (CIN) is a driver of cancer metastasis1–4, yet the extent to which this effect depends on the immune system remains unknown. Using ContactTracing—a newly developed, validated and benchmarked tool to infer the nature and conditional dependence of cell–cell interactions from single-cell transcriptomic data—we show that CIN-induced chronic activation of the cGAS–STING pathway promotes downstream signal re-wiring in cancer cells, leading to a pro-metastatic tumour microenvironment. This re-wiring is manifested by type I interferon tachyphylaxis selectively downstream of STING and a corresponding increase in cancer cell-derived endoplasmic reticulum (ER) stress response. Reversal of CIN, depletion of cancer cell STING or inhibition of ER stress response signalling abrogates CIN-dependent effects on the tumour microenvironment and suppresses metastasis in immune competent, but not severely immune compromised, settings. Treatment with STING inhibitors reduces CIN-driven metastasis in melanoma, breast and colorectal cancers in a manner dependent on tumour cell-intrinsic STING. Finally, we show that CIN and pervasive cGAS activation in micronuclei are associated with ER stress signalling, immune suppression and metastasis in human triple-negative breast cancer, highlighting a viable strategy to identify and therapeutically intervene in tumours spurred by CIN-induced inflammation.
Suggested Citation
Jun Li & Melissa J. Hubisz & Ethan M. Earlie & Mercedes A. Duran & Christy Hong & Austin A. Varela & Emanuele Lettera & Matthew Deyell & Bernardo Tavora & Jonathan J. Havel & Su M. Phyu & Amit Dipak A, 2023.
"Non-cell-autonomous cancer progression from chromosomal instability,"
Nature, Nature, vol. 620(7976), pages 1080-1088, August.
Handle:
RePEc:nat:nature:v:620:y:2023:i:7976:d:10.1038_s41586-023-06464-z
DOI: 10.1038/s41586-023-06464-z
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:620:y:2023:i:7976:d:10.1038_s41586-023-06464-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.